Adenovirus-Mediated Delivery of Decoy Hyper Binding Sites Targeting Oncogenic HMGA1 Reduces Pancreatic and Liver Cancer Cell Viability.

Autor:	Hassan F; Department of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA., Ni S; Department of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA., Arnett TC; Department of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA., McKell MC; Department of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA., Kennedy MA; Department of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA.
Jazyk:	angličtina
Zdroj:	Molecular therapy oncolytics [Mol Ther Oncolytics] 2018 Jan 31; Vol. 8, pp. 52-61. Date of Electronic Publication: 2018 Jan 31 (Print Publication: 2018).
DOI:	10.1016/j.omto.2018.01.002
Abstrakt:	High mobility group AT-hook 1 (HMGA1) protein is an oncogenic architectural transcription factor that plays an essential role in early development, but it is also implicated in many human cancers. Elevated levels of HMGA1 in cancer cells cause misregulation of gene expression and are associated with increased cancer cell proliferation and increased chemotherapy resistance. We have devised a strategy of using engineered viruses to deliver decoy hyper binding sites for HMGA1 to the nucleus of cancer cells with the goal of sequestering excess HMGA1 at the decoy hyper binding sites due to binding competition. Sequestration of excess HMGA1 at the decoy binding sites is intended to reduce HMGA1 binding at the naturally occurring genomic HMGA1 binding sites, which should result in normalized gene expression and restored sensitivity to chemotherapy. As proof of principle, we engineered the replication defective adenovirus serotype 5 genome to contain hyper binding sites for HMGA1 composed of six copies of an individual HMGA1 binding site, referred to as HMGA-6. A 70%-80% reduction in cell viability and increased sensitivity to gemcitabine was observed in five different pancreatic and liver cancer cell lines 72 hr after infection with replication defective engineered adenovirus serotype 5 virus containing the HMGA-6 decoy hyper binding sites. The decoy hyper binding site strategy should be general for targeting overexpression of any double-stranded DNA-binding oncogenic transcription factor responsible for cancer cell proliferation.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu